| Revision as of 08:57, 22 January 2014 editJim1138 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers297,704 editsm rv broke links, some material copy/pasted from http://issuu.com/rivegauche/docs/ihp_april_edition_2012 (HG)← Previous edit | Revision as of 09:00, 22 January 2014 edit undo174.112.42.106 (talk) →Medical uses: actual medicinal use and indicationNext edit → | ||
| (One intermediate revision by the same user not shown) | |||
| Line 11: | Line 11: | ||
| |publisher=}}</ref> headquartered in ], Alberta, Canada, the company and lead product was acquired by Valeant Pharmaceuticals International (headquartered in Laval, Quebec, Canada) in 2011. | |publisher=}}</ref> headquartered in ], Alberta, Canada, the company and lead product was acquired by Valeant Pharmaceuticals International (headquartered in Laval, Quebec, Canada) in 2011. | ||
| It is approved for use to "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system".<ref>http://webprod3.hc-sc.gc.ca/lnhpd-bdpsnh/info.do?lang=eng&licence=80002849</ref> | |||
| ==Medical uses== | ==Medical uses== | ||
| It is approved for use to "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system" | |||
| There is no evidence that Cold-fX is effective in those infected with the ].<ref name=Nah2011>{{cite journal|last=Nahas|first=R|coauthors=Balla, A|title=Complementary and alternative medicine for prevention and treatment of the common cold.|journal=Canadian family physician Medecin de famille canadien|date=2011 Jan|volume=57|issue=1|pages=31–6|pmid=21322286}}</ref> The effect of preventative use is not clear.<ref name=Nah2011/> When used preventatively it makes no difference on the rate of infections.<ref name=Seida2011>{{cite journal|last=Seida|first=JK|coauthors=Durec, T; Kuhle, S|title=North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review.|journal=Evidence-based complementary and alternative medicine : eCAM|year=2011|volume=2011|pages=282151|pmid=19592479}}</ref> It also appears to have no effect on how bad the infections are.<ref name=Seida2011/> There is tentative evidence that it may lesson the length of sickness when used preventatively.<ref name=Seida2011/> | |||
| ==Adverse effects== | ==Adverse effects== | ||
Revision as of 09:00, 22 January 2014
 | The topic of this article may not meet Misplaced Pages's notability guidelines for products and services. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Cold-fX" – news · newspapers · books · scholar · JSTOR (January 2014) (Learn how and when to remove this message) |
Cold-fX is a product derived from the roots of North American ginseng (Panax quinquefolius). Originally manufactured by Afexa Life Sciences Inc. (formerly called CV Technologies Inc.), headquartered in Edmonton, Alberta, Canada, the company and lead product was acquired by Valeant Pharmaceuticals International (headquartered in Laval, Quebec, Canada) in 2011.
It is approved for use to "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system".
Medical uses
It is approved for use to "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system"
Adverse effects
Individuals requiring anti-coagulant therapy such as warfarin should avoid use of COLD-FX. Not recommended for individuals with impaired liver or renal function. Do not exceed the recommended daily dose.
Individuals with known allergies to ginseng should avoid use of COLD-FX. Do not use if you are pregnant or breastfeeding.
Other adverse effects include: headaches, anxiety, trouble sleeping and an upset stomach.
Criticism
There is doubts in the medical and scientific community that Cold-fX is effective. All the studies posing 'significant' results favoring the efficacy of ColdFX have been funded by the manufacturer.
Other criticisms point out that these studies have been small scale, with conspicuously shallow participant pools and lopsided gender distributions. Researchers have pointed out that there aren't enough studies on the effects of any form of Ginseng on the common cold to form any conclusions.
Scientists have argued that Cold-fX has not been tested for its ability to treat a cold after an individual has been infected. In addition, no studies have yet been performed to assess the possible long term side effects of taking the pills every day during the cold and flu season. Afexa Life Sciences Inc. (formerly called CV Technologies Inc.), the makers of Cold-fX, were criticized for making health claims about the product that have never been tested or verified scientifically. Up until February 2007, the company advised a regimen of 18 pills over a course of 3 days in order to obtain "immediate relief" from a cold. Health Canada's review of the scientific literature confirmed that this is not a claim that CV Technologies Inc. is entitled to make. The company formulated a separate product for this usage. A CV Technologies press release explained the change in the dosing regimen as a choice to take a two-tier approach application to Health Canada.
References
- "What is COLD-fX intended for?". Cold-fX: Frequently Asked Questions. Retrieved 2007-11-24.
- http://webprod3.hc-sc.gc.ca/lnhpd-bdpsnh/info.do?lang=eng&licence=80002849
- Cite error: The named reference
Nah2011was invoked but never defined (see the help page). - ^ Cite error: The named reference
Seida2011was invoked but never defined (see the help page). - ^ "Fighting the Common Cold". ABC News. 2005-10-25.
- William Lin (2007-02-16). "Does ginseng really work? It depends on who you ask". The Ottawa Citizen.
- "Ginseng Unproven in U.S." Los Angeles Times. 2008-02-18.
- Charlie Gillis (2007-03-26). "COLD-fX catches the sniffles again". Macleans Magazine.
- "COLD-fX Sets Record Straight: Health Canada's Approval of New Medical Claims Unchanged" (PDF). CV Technologies. March 5, 2007.